1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Morphosys Ag: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma Maplirpacept, Tafasitamab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 6 | 2023-08-04 | 2025-09-05 |
Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Recurrence (1)
Lenalidomide (1) · tafasitamab (1)
Japan (1) · South Korea (1) · United States (1)